Antisense oligonucleotide: Began a Phase I trial.

Lynx Therapeutics Inc., Foster City, Calif. Product: Antisense oligonucleotide that blocks the mRNA of p53 gene Indication: Treat acute myelogenous leukemia Status: Began a Phase I trial ...